A Phase I Trial of LY3143921 Hydrate in Solid Tumours

This clinical study looked at a drug called LY3143921 hydrate, which is a Cdc7 inhibitor. Cdc7 helps our cells replicate correctly. Cdc7 is usually found at a low level in normal cells but can reach higher levels in cancer cells. This is often the case in certain types of solid tumour cancers, which we focused on in this study. It was thought that giving LY3143921 hydrate would block the function of Cdc7 and would affect cancer cells by stopping their replication and causing them to die. LY3143921 hydrate looked promising in laboratory studies and studies in animals. This clinical study had two parts: Part 1 - a 'dose escalation' phase where groups of patients received increasing doses of LY3143921 hydrate to find a safe dose and a dose that best targeted the cancer cells. Part 2 - an 'expansion' phase where a larger group of patients received the highest dose of LY3143921 hydrate considered to be safe from Part 1, to find out more about how the drug was working.